Bone Biologics Corp · NASDAQ:BBLG
Bone Biologics — Investor Presentation (2019)
21 slides from Bone Biologics's investor presentation, 2019
Slide 1: Regenerative Medicine for Bone
Regenerative Medicine for Bone 2019 Confidential & Proprietary 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement This document does not constitute or form part of an invitation or recommendation to subscribe for or purchase any securities. The distribution may be restricted by law in certain jurisdictions and persons into whose possession this document comes should inform themselves about
Slide 3: Overview
Overview Bone Biologics is redefining bone regeneration with Nell‐1, a growth factor that has demonstrated to effectively increase the quantity and quality of bone across small and large animal models. Confidential & Proprietary 3
Slide 4: Healthcare Trends
Healthcare Trends With an aging population, musculoskeletal diseases are becoming a greater burden as the cost of treating long‐term pain and disability increases. People are seeking a more active lifestyle, therefore “Quality of Life” is becoming more important. Bone regeneration is a significant m
Slide 5: Bone Biologics Attractiveness
Bone Biologics Attractiveness • 3 billion global market opportunity in spine fusion Opportunity • Additional indications in trauma and osteoporosis 1 • Strong technology discovered at UCLA Technology • Proprietary product platform with strong IP • Pre‐clinical studies have shown increases in fusion
Slide 6: Bone Biologic's Solution To Unmet Need
Bone Biologic’s Solution To Unmet Need A major challenge in orthopedic surgery is effective bone regeneration Challenges w/ rhBMPs Proposed Nell‐1 Solution Rapid bone growth (egg Rapid / healthy bone growth shelling) Forms bone in target specific Cysts & less dense bone fashion without induc
Slide 7: Nell-1 Product Pipeline
Nell‐1 Product Pipeline 1 Clinical Discovery Pre‐Clinical Phase I/II Phase III Market Size/ Indication Leader $3.0 B Spine Fusion InFuse (MDT) = >$500 M Trauma $11.2 B Osteoporosis Prolia(AMGN) = $2.3 B Forteo (LLY) = $1.6 B Confidential Source: & NOF Company Reports, Proprietary 7
Slide 8: Nell-1 Mechanism of Action
Nell‐1 Mechanism of Action Runx2 Protein is known as the “Master Switch” responsible for bone formation BBC’s NELL-1 Protein helps committed cells grow better bone or cartilage (depending upon cell type) rhBMP-2 targets many cells ---- May lead to tissue formation in undesirable anatomical loc
Slide 9: More Than 45 Publications on Nell-1
More Than 45 Publications on Nell‐1 Novel Wnt Nfatc2 is a NELL‐1 protein The effect of “The study of NELL‐1 induced “Human NELL‐1 Regulator NEL‐ primary promotes bone NELL‐1 and NELL‐1 gene bone Expressed in Like Molecule‐1 response gene of formation in a bone modified goat regeneration in Unilatera
Slide 10: Pilot Large-Animal Study
Pilot Large‐Animal Study Clinically relevant sheep study demonstrated that rhNELL-1 increases the fusion rate and quantity of bone compared to sDBX Confidential & Proprietary 10
Slide 11: Strong IP Barrier
Strong IP Barrier 13 issued patents with more than 200 claims covering: Molecular Structure ‐ Composition Manufacturing Process ‐ NELL‐1 protein expressed in mammalian & other systems Field of Use – Use for promoting bone growth Exclusive license to NELL‐1 technology from UCLA for spine, t
Slide 12: Large Addressable Market
Large Addressable Market $3 Billion Global Bone Graft Substitute Market We estimate about 13% market share for BBC ~5 years after commercialization Sources: Orthopedic Confidential Network News & Proprietary 12
Slide 13: Revenue Estimates for Spine Indication
Revenue Estimates for Spine Indication We assume reasonable penetration rates of NELL-1 due to an attractive safety and efficacy profile, at a reasonable price. YEAR 1 YEAR 2 YEAR 3 YEAR 4 YEAR 5 Annual WW Lumbar spine fusion procedures 500,000 500,000 500,000 500,000 500,000 Revenues $46,875,000 $1
Slide 14: Future Valuation Estimates
Future Valuation Estimates We assume approximately $191M of revenues in second full year of commercialization, resulting in approximately 20% penetration in lumbar spine fusion procedures. Target ‐50% Valuation +25% Bear Case Base Case Bull Case 10% Penetration 20% Penetration 25% Penetration $320M
Slide 15: Product Development Milestones
Product Development Milestones Final Nell-1 Commence cell line Commence OUS Pivotal sheep Phase I/II FDA selected and study Clinical Approval synthesized 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Pilot sheep Pivotal sheep Commence US study data study data Phase III Clinical Confidential & Pr
Slide 16: Key Metrics
Key Metrics • September 19, 2014 – Reversed merge into shell corp. • March 31, 2016 – Commenced trading on OTC QB 1 History • July 16, 2018 Reverse stock split • ~18M Diluted shares o/s ** • Raised $23M to date Financial • Company needs ~$20M to complete First in Man Trial Metrics ** 30M shares outs
Slide 17: Ortho M&A
Ortho M&A PURCHASE PRICE/SALES TARGET ACQUIRER PRICE ($‐m) TTM REVENUES MULTIPLE DATE Paragon Medical NN Inc $375 $138 2.7 Apr‐18 Spinal Kinetics OrthoFix $105 $30 3.5 Mar‐18 Exactech TPG Capital $625 $260 2.4 Oct‐17 Dfine Merit Medical $98 $32 3.0 Jul‐16 LDR Spine Medtronic $1,000 $166 6.0 Jun‐16 C
Slide 18: Value Proposition to Stakeholders
Value Proposition to Stakeholders 1 • Reduced costs Payors • Safer treatment ‐‐‐ less complications • Fewer reoperations • Consumers more selective, demand better care Patients • Better safety profile • Improved fusions and healing • Improved clinical outcomes will see physicians/health systems driv
Slide 19: Management Team
Management Team Jeffrey Frelick, CEO and President COO Life Science Enterprises 15 yrs. Med‐Tech analyst, Canaccord, ThinkEquity, Lazard, Leerink Consultant, Boston Biomedical Consultants Regional Sales Mgr., Becton Dickinson PCD Laboratory Technologist, Clinical Pathology Facility Deina W
Slide 20: Board of Directors
Board of Directors Don Hankey Bruce Stroever Chairman of the Board Bone Biologics / CEO Hankey Group Former CEO Musculoskeletal Transplant Foundation Mr. Hankey holds his BA and post‐graduate work from University Mr. Stroever served as Chairman of Bone Biologics from 2012 ‐ 2018 and of Southern Cali
Slide 21: www.bonebiologics.com OTC QB: BBLG
1 2 Burlington Woods Dr, Suite 100 Burlington, MA 01803 781‐552‐4452 www.bonebiologics.com OTC QB: BBLG Confidential & Proprietary 21